First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

标题
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
作者
关键词
-
出版物
NEW ENGLAND JOURNAL OF MEDICINE
Volume 383, Issue 21, Pages 2018-2029
出版商
Massachusetts Medical Society
发表日期
2020-11-19
DOI
10.1056/nejmoa2027187

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started